Equities Analysts Offer Predictions for Adagene Inc.’s FY2025 Earnings (NASDAQ:ADAG)

Adagene Inc. (NASDAQ:ADAG) – Research analysts at Jefferies Financial Group lowered their FY2025 earnings per share estimates for Adagene in a note issued to investors on Tuesday, December 7th. Jefferies Financial Group analyst K. Shi now forecasts that the company will post earnings of ($5.50) per share for the year, down from their previous estimate of ($5.20).

Separately, Zacks Investment Research raised shares of Adagene from a “sell” rating to a “hold” rating in a research report on Wednesday, October 27th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $33.89.

Shares of ADAG opened at $9.67 on Friday. Adagene has a twelve month low of $7.37 and a twelve month high of $31.83. The firm’s fifty day simple moving average is $10.97 and its 200-day simple moving average is $13.98.

Institutional investors have recently modified their holdings of the business. Millennium Management LLC purchased a new position in Adagene during the 2nd quarter worth $298,000. Alyeska Investment Group L.P. grew its position in Adagene by 280.5% during the 2nd quarter. Alyeska Investment Group L.P. now owns 40,000 shares of the company’s stock worth $542,000 after purchasing an additional 29,488 shares during the last quarter. Trellus Management Company LLC grew its position in Adagene by 34.5% during the 2nd quarter. Trellus Management Company LLC now owns 55,000 shares of the company’s stock worth $746,000 after purchasing an additional 14,093 shares during the last quarter. E Fund Management Co. Ltd. purchased a new position in Adagene during the 3rd quarter worth $851,000. Finally, Morgan Stanley purchased a new position in Adagene during the 1st quarter worth $8,167,000. 13.50% of the stock is currently owned by institutional investors.


A small, rapidly expanding Seattle cannabis company is gaining attention from investors. Founded by two cannabis veterans, the company has increased sales 8-fold since inception. Now selling for less than $1 per share, this is an opportunity to acquire thousands of shares – a potential windfall.

Adagene Company Profile

Adagene Inc, a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. Its lead product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase Ib clinical trials for the treatment advanced solid tumors and non-Hodgkin’s lymphoma; ADG126, a fully-human anti-CTLA-4 mAb for cancer treatment; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of various tumors.

Read More: How are the companies in the S&P 500 selected?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Adagene right now?

Before you consider Adagene, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Adagene wasn’t on the list.

While Adagene currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here


Source link

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button